Sasaki J et al. |
Microbial transformation of 6-O-methylerythromycin derivatives. |
1988 |
J. Antibiot. |
pmid:2971032
|
Adachi T et al. |
14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human. |
1988 |
J. Antibiot. |
pmid:2971033
|
Barry AL et al. |
In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. |
1988 |
Antimicrob. Agents Chemother. |
pmid:2840016
|
Segreti J et al. |
In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952061
|
Benson CA et al. |
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952063
|
Barry AL et al. |
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2952064
|
Chin NX et al. |
Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2953303
|
Bowie WR et al. |
In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2953304
|
Hanson CW et al. |
Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031). |
1987 |
J. Clin. Microbiol. |
pmid:2954995
|
Floyd-Reising S et al. |
In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2955742
|
Fernandes PB et al. |
Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. |
1987 |
Antimicrob. Agents Chemother. |
pmid:2957954
|
Fernandes PB et al. |
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. |
1986 |
Antimicrob. Agents Chemother. |
pmid:2949695
|
Morimoto S et al. |
Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. |
1984 |
J. Antibiot. |
pmid:6706855
|
Pike VW et al. |
Semi-automated preparation of a 11C-labelled antibiotic--[N-methyl-11C]erythromycin A lactobionate. |
1984 |
Int J Appl Radiat Isot |
pmid:6231252
|
Monego F et al. |
Molecular identification and typing of Mycobacterium massiliense isolated from postsurgical infections in Brazil. |
|
Braz J Infect Dis |
pmid:22230849
|
Kekilli M et al. |
Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. |
|
Saudi J Gastroenterol |
pmid:27748322
|
Colomina RodrÃguez J et al. |
[Impact of Integrated Model for Rational Use of Antibiotics in a health area (project MIURA)]. |
|
Rev. Esp. Salud Publica |
pmid:20661527
|
Mishra A et al. |
A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin. |
|
Indian J Pharmacol |
pmid:25298587
|
Wang J et al. |
Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study. |
|
Saudi J Gastroenterol |
pmid:26655129
|
Pellicano R and Fagoonee S |
One or two weeks of treatment with Helicobacter Pylori ''standard'' triple therapy in the year 2015? |
|
Saudi J Gastroenterol |
pmid:26655127
|